Why Humacyte Stock Is Trading 15% Higher Monday

Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration's Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered

Benzinga01:39

Humacyte Stock Rallies 19% on FDA RMAT Designation

Seeking AlphaJul 1 23:06

Humacyte Announces Third RMAT Designation By FDA For ATEV - Quick Facts

RTTNewsJul 1 21:33

Humacyte Shares Jump on FDA's Special Status Award

By Dean Seal Shares of Humacyte gained after the company said regulators have granted a special advanced-therapy designation to its implant for vascular replacement and repair. The stock was up 10%

WSJJul 1 21:12

Humacyte's ATEV Treatment Gets New FDA Designation; Shares Rise Pre-Bell

Humacyte (HUMA) said Monday its investigational Acellular Tissue Engineered Vessel, or ATEV, was granted the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for pa

MT NewswiresJul 1 20:45

Express News | Humacyte Acellular Tissue Engineered Vessel (Atev™) Receives Fda’s Regenerative Medicine Advanced Therapy (Rmat) Designation for Patients With Advanced Peripheral Artery Disease (Pad)

BreakingsJul 1 20:01